JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.85B |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$1.5B |
| 3 |
JPMorgan BetaBuilders Canada ETF
BBCA
|
+$1.21B |
| 4 |
Chevron
CVX
|
+$1.08B |
| 5 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$986M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$3.61B |
| 2 |
Occidental Petroleum
OXY
|
+$1.36B |
| 3 |
Merck
MRK
|
+$913M |
| 4 |
Visa
V
|
+$801M |
| 5 |
AT&T
T
|
+$771M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.95% |
| 2 | Technology | 12.9% |
| 3 | Financials | 12.36% |
| 4 | Healthcare | 9.31% |
| 5 | Consumer Discretionary | 8.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
LUNA
5076
DELISTED
Luna Innovations Incorporated
LUNA
| $39K | ﹤0.01% |
9,086
+1,844
| +25% | +$7.91K |
2017 Q3
7 quarters
|
|
5077
Aldeyra Therapeutics
ALDX
$58.4M
| $38K | ﹤0.01% |
6,195
+1,041
| +20% | +$7.83K |
2017 Q4
6 quarters
|
|
5078
Anavex Life Sciences
AVXL
$162M
| $38K | ﹤0.01% |
+11,791
| New | +$36.6K |
2019 Q2
0 quarters
|
|
5079
Cadiz
CDZI
$314M
| $38K | ﹤0.01% |
3,517
-1,999
| -36% | -$20.4K |
2017 Q4
6 quarters
|
|
5080
Cue Biopharma
CUE
$168M
| $38K | ﹤0.01% |
165
+21
| +15% | +$5.22K |
2018 Q1
5 quarters
|
|
5081
Matinas BioPharma
MTNB
$2.48M
| $38K | ﹤0.01% |
60
| – | – |
2017 Q2
8 quarters
|
|
|
CHAP
5082
DELISTED
Chaparral Energy, Inc.
CHAP
| $38K | ﹤0.01% |
8,533
-87,954
| -91% | -$440K |
2018 Q3
3 quarters
|
|
|
FNJN
5083
DELISTED
Finjan Holdings, Inc.
FNJN
| $38K | ﹤0.01% |
17,115
-13,266
| -44% | -$35.7K |
2018 Q1
5 quarters
|
|
|
BPT
5084
DELISTED
BP Prudhoe Bay Royalty Trust
BPT
| $37K | ﹤0.01% |
+2,406
| New | +$47.3K |
2019 Q2
0 quarters
|
|
|
EFR
5085
Eaton Vance Senior Floating-Rate Fund
EFR
$301M
| $37K | ﹤0.01% |
2,841
| – | – |
2018 Q3
3 quarters
|
|
5086
VanEck International High Yield Bond ETF
IHY
$39.4M
| $37K | ﹤0.01% |
1,500
-793
| -35% | -$19.4K |
2017 Q1
9 quarters
|
|
5087
OP Bancorp
OPBK
$229M
| $37K | ﹤0.01% |
3,565
-88
| -2% | -$853 |
2018 Q2
4 quarters
|
|
5088
Tilray
TLRY
$550M
| $37K | ﹤0.01% |
79
+59
| +295% | +$28.2K |
2018 Q3
3 quarters
|
|
5089
Union Bankshares
UNB
$114M
| $37K | ﹤0.01% |
1,069
-53
| -5% | -$1.99K |
2017 Q4
6 quarters
|
|
|
ZYXI
5090
DELISTED
Zynex
ZYXI
| $37K | ﹤0.01% |
4,705
+4,265
| +969% | +$27.8K |
2019 Q1
1 quarter
|
|
|
FNCB
5091
DELISTED
FNCB Bancorp Inc. Common Stock
FNCB
| $37K | ﹤0.01% |
4,699
+3,071
| +189% | +$23.7K |
2019 Q1
1 quarter
|
|
|
FCCY
5092
DELISTED
1st Constitution Bancorp
FCCY
| $37K | ﹤0.01% |
2,060
+270
| +15% | +$5.03K |
2018 Q2
4 quarters
|
|
|
ADMS
5093
DELISTED
Adamas Pharmaceuticals
ADMS
| $37K | ﹤0.01% |
6,202
+773
| +14% | +$4.45K |
2014 Q2
20 quarters
|
|
|
TLGT
5094
DELISTED
Teligent, Inc
TLGT
| $37K | ﹤0.01% |
5,989
+4,985
| +497% | +$40.6K |
2017 Q4
6 quarters
|
|
|
PRGX
5095
DELISTED
PRGX Global, Inc.
PRGX
| $37K | ﹤0.01% |
5,724
-3,260
| -36% | -$23.4K |
2017 Q4
6 quarters
|
|
|
REV
5096
DELISTED
Revlon, Inc.
REV
| $37K | ﹤0.01% |
1,896
-540
| -22% | -$11.8K |
2017 Q3
7 quarters
|
|
5097
Ascent Industries
ACNT
$124M
| $36K | ﹤0.01% |
2,284
+267
| +13% | +$4.6K |
2018 Q2
4 quarters
|
|
5098
Alphatec Holdings
ATEC
$1.62B
| $36K | ﹤0.01% |
+8,199
| New | +$30.6K |
2019 Q2
0 quarters
|
|
5099
LSI Industries
LYTS
$787M
| $36K | ﹤0.01% |
10,000
-29,805
| -75% | -$102K |
2013 Q2
24 quarters
|
|
|
OTRK
5100
DELISTED
Ontrak
OTRK
| $36K | ﹤0.01% |
22
-151
| -87% | -$226K |
2019 Q1
1 quarter
|
|
Similar funds
JP Morgan Chase's Q2 2019 Portfolio in Review
As of Q2 2019, JP Morgan Chase held 6,226 positions worth $511B, up 4.5% from $490B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase's Q2 2019 filing shows 458 new, 2,668 increased, 2,116 reduced and 420 closed positions. Its largest new stake was Corteva: 13,119,143 shares worth $388M. The largest sale was iShares 1-3 Year Treasury Bond ETF, an estimated $3.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 28% of assets, up from 27% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q2 2019 buy was Corteva: 13,119,143 shares worth $388M.
- JP Morgan Chase added most to iShares 0-1 Year Treasury Bond ETF in Q2 2019, an estimated $3.85B increase.
- JP Morgan Chase's biggest Q2 2019 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $3.61B.
- JP Morgan Chase fully exited Goldcorp Inc in Q2 2019, selling an estimated $131M.
- JP Morgan Chase's ten largest holdings make up 16% of its $511B portfolio in Q2 2019.
- JP Morgan Chase opened 458 new positions and closed 420 in Q2 2019.
- JP Morgan Chase's portfolio value rose 4.5% quarter-over-quarter to $511B.
Based on JP Morgan Chase's 13F filing for Q2 2019, filed 7 Aug 2019.